Syndax Pharmaceuticals, Inc. (SNDX)
19.57
-0.08
(-0.41%)
USD |
NASDAQ |
Aug 24, 16:00
19.70
+0.13
(+0.66%)
Pre-Market: 20:00
Syndax Pharmaceuticals Debt to Equity Ratio : 39.03 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 39.03 |
| March 31, 2026 | 8.298 |
| December 31, 2025 | 5.345 |
| September 30, 2025 | 2.993 |
| June 30, 2025 | 2.195 |
| March 31, 2025 | 1.607 |
| December 31, 2024 | 1.20 |
| September 30, 2024 | 0.0023 |
| June 30, 2024 | 0.0026 |
| March 31, 2024 | 0.0028 |
| December 31, 2023 | 0.003 |
| September 30, 2023 | 0.0052 |
| June 30, 2023 | 0.0052 |
| March 31, 2023 | 0.0024 |
| December 31, 2022 | 0.0025 |
| September 30, 2022 | 0.0037 |
| June 30, 2022 | 0.0583 |
| March 31, 2022 | 0.0561 |
| December 31, 2021 | 0.0513 |
| September 30, 2021 | 0.1088 |
| June 30, 2021 | 0.0968 |
| March 31, 2021 | 0.091 |
| December 31, 2020 | 0.0814 |
| September 30, 2020 | 0.1557 |
| Date | Value |
|---|---|
| June 30, 2020 | 0.1393 |
| March 31, 2020 | 0.3846 |
| December 31, 2019 | 0.0284 |
| September 30, 2019 | 0.0228 |
| June 30, 2019 | 0.0227 |
| March 31, 2019 | 0.0197 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| September 30, 2014 | -3.808 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
| December 31, 2013 | 0.00 |
| September 30, 2013 | -1.692 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Viking Therapeutics, Inc. | 0.01 |
| Kura Oncology, Inc. | 0.5049 |
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 703.65M |
| Total Liabilities (Quarterly) | 688.55M |
| Shareholders Equity (Quarterly) | 15.10M |
| Current Ratio | 6.772 |
| Net Debt Paydown Yield | -2.50% |